Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions of tocol-soluble therapeutics

a tocol-soluble and therapeutic technology, applied in the field of tocol-soluble therapeutic compositions, can solve the problems of water-soluble agents or amphiphilic agents, lipophilic agents, subject to degradation, etc., and achieve the effect of improving the therapeutic effect and rapid clearan

Inactive Publication Date: 2004-03-18
SONUS PHARM INC
View PDF6 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The invention is about a new way to make pharmaceutical compositions that can dissolve certain drugs in a special oil called tocopherols. This oil can be mixed with other oils to make emulsions or gel-based systems for different types of administration like injection or oral. The invention also includes the use of liposomes, which are tiny bubbles made of fat that can encapsulate drugs and improve their solubility. The invention can make the drugs more soluble in the oil phase, which can reduce toxicity and improve their efficacy."

Problems solved by technology

However, only selected lipophilic active agents are highly soluble in tocopherols and tocotrienols.
Furthermore, lipophilic agents that are charged tend to remain associated with the water or plasma, where they may be subject to degradation, even while residing in part in the oil phase.
Finally, some water-soluble agents or amphiphilic agents that could benefit from the advantages of a tocopherol or tocotrienol formulation are not readily soluble in these oils.
These formulations are particularly valuable for water-loving drugs and macromolecules but may not provide the advantages of solubilizing the drug directly in the oil.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions of tocol-soluble therapeutics
  • Compositions of tocol-soluble therapeutics
  • Compositions of tocol-soluble therapeutics

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0050] Tocol-Soluble Ion Pair Formulation of Clarithromycin for Intravenous Administration.

[0051] Clarithromycin is a macrolide antibiotic widely prescribed for a variety of bacterial infections. Other important members of this class of drugs include azithromycin and erythromycin. Macrolide antibiotics are primarily given orally, although intravenous dosing is indicated in some cases. Macrolides are known for causing venous irritation / pain on injection, so they are generally given in dilute (2 mg / mL) solutions by slow infusion (total daily doses can be in gram quantities).

[0052] Clarithromycin free base is poorly water soluble but can be solubilized in water as a water-soluble salt, for example the lactobionate or glucoheptonate, solutions of which display the aforementioned venous irritation. The relative lipophilicity of clarithromycin has led various investigators to propose a variety of lipid dispersed systems, such as liposomes, mixed micelles, and oil-in-water (o / w) emulsions ...

example 2

[0057] Stability of Clarithromycin Formulation

[0058] The physical and chemical stability of the formulation of Example 1 at 4.degree. C. was followed for 6 months. No detectable physical change in the microemulsion incorporating a tocol-soluble ion-pair could be detected by gross examination or by measuring emulsion droplet size using standard particle sizing methods. Likewise, no detectable degradation of clarithromycin could be detected by HPLC. In contrast, a solution of the lactobionate salt had degraded by about 50% over the same time period. Thus, the microemulsion when stored at 4.degree. C. remained stable for at least 6 months.

example 3

[0059] Amiodarone as a Tocol-Soluble Ion Pair Compound

[0060] Amiodarone is a Class III anti-arrhythmic for care of patients suffering or at risk of heart attack. Since 1977, it has been administered as an aqueous solution of the HCl salt in 10% Tween 80 and 2% benzyl alcohol under the tradename Cordarone.RTM. IV.

[0061] Amiodarone was purchased as the HCl salt (Sigma Chemicals, St Louis Mo.). The free base was prepared by dissolving the drug in chloroform and washing the organic phase with saturated sodium bicarbonate. The drug in the organic phase was then recovered as a pale yellow oil. An emulsion containing 12 mg / mL amiodarone as the free base was then formulated as follows:

2 Weight in Final Percent Component Oil Phase (%) d,1-a-tocopherol 1.0 gm 2.0% TPGS 1.6 gm 3.2% Poloxamer 407 0.25 gm 0.5% Amiodarone (free base) 0.6 gm 1.2% Vitamin E Succinate 0.5 gm 1.0% PEG-400 3.0 gm 6.0% Buffer to pH 5.0 qs to 50 mL

[0062] The formulation uses a molar equivalent of amiodarone as the free ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
mean diameteraaaaaaaaaa
mean droplet diameteraaaaaaaaaa
mean droplet diameteraaaaaaaaaa
Login to View More

Abstract

Tocol-based compositions of charged amphiphilic and water soluble pharmaceutically active compounds or their charged precursors are prepared by forming a tocol-soluble ion pair with an oppositely charged ion-pair forming compound capable of forming a tocol-soluble ion-pair with the active compound. Also disclosed are novel compounds tocopherolsuccinate-aspartate and tocopherolsuccinate-glutamate, which are useful as ion-pair forming compounds.

Description

BACKGROUND AND PRIOR ART[0001] The invention is directed to compositions having an oil phase that contains pharmaceutically active ingredients that are charged amphiphilic or water soluble. The compositions generally comprise tocol-soluble ion pairs in a tocol-based oil of a multiphasic system or a precursor of such a system. The compositions of the invention can be in the form of an emulsion, liquid crystalline gel, self-emulsifying drug delivery system, or a liposomal or niosomal dispersion for oral or parenteral administration, which term is meant to include, for instance, intravenous, subcutaneous, intraperitoneal, intramuscular, pulmonary, intranasal, and topical administration such as transdermal and ocular. Emulsions or microemulsions and self-emulsifying drug delivery systems are the preferred form of the compositions of the present invention.[0002] Emulsions, and emulsification as a composition and method of administration of pharmaceuticals, have a long history in the medi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/10A61K9/107A61K9/127A61K31/131A61K31/132A61K31/17A61K31/19A61K31/194A61K31/4045A61K31/407A61K31/417A61K31/4709A61K31/4745A61K31/475A61K31/496A61K31/7004A61K31/704A61K31/7048A61K31/7084A61K31/7088A61K31/715A61K38/00A61K45/00A61K47/08A61K47/10A61K47/12A61K47/22A61K47/24A61K47/28A61K47/44A61P5/02A61P5/38A61P9/00A61P9/06A61P9/08A61P25/04A61P25/06A61P25/18A61P25/20A61P25/22A61P25/24A61P29/00A61P31/04A61P31/10A61P31/12A61P37/06A61P37/08A61P39/02A61P43/00
CPCA61K9/0019A61K9/1075Y10S977/907Y10S514/937Y10S514/938A61K47/22A61P25/04A61P25/06A61P25/18A61P25/20A61P25/22A61P25/24A61P29/00A61P31/04A61P31/10A61P31/12A61P37/06A61P37/08A61P39/02A61P43/00A61P5/02A61P5/38A61P9/00A61P9/06A61P9/08
Inventor CONSTANTINIDES, PANAYIOTIS P.LAMBERT, KAREL J.TUSTIAN, ALEXANDER K.NIENSTEDT, ANDREW M.
Owner SONUS PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com